Australia, take a bow -- you've proved you can compete in the global clinical trials market. But let's not get too complacent, writes Graeme Blackman. [ + ]

Ruth Beran wraps up a recent report that gives Australia a high rating against other major centres of pharma R&D. [ + ]

Ruth Beran looks at some of the many highlights expected at the 2005 AusBiotech national conference in Perth, which kicks off on Monday. [ + ]

Kiran Mazumdar-Shaw spoke with Melissa Trudinger about ways in which India and Australia can work together in biotech. [ + ]

Since she took the top job at AusBiotech on the eve of the BIO conference earlier this year, Anna Lavelle has done a lot of listening. Now she's ready to talk -- about her role and her vision for the organisation. [ + ]

Australia's best-known and most venerable medical research institute, The Walter and Eliza Hall Institute of Medical Research in Parkville, Melbourne, celebrates its 90th anniversary this year. Graeme O'Neill interviewed the Hall's former director, Prof Sir Gustav Nossal, and his successor, Prof Suzanne Cory, about the institute's history and their view of science in Australia today. [ + ]

The new AusBiotech/ASX code of practice for reporting by life science companies, launched last week, is being hailed as an important milestone in the development of the Australian biotech sector. Here, Michael Aldridge, who was on the committee to review the code's first draft, explains why he believes the code is so important to the industry. [ + ]

The new AusBiotech/ASX code of practice for reporting by life science companies, launched last week, is being hailed as an important milestone in the development of the Australian biotech sector. Here, Igor Gonda, who was on the committee to review the code's first draft, explains why he believes the code is so important to the industry. [ + ]

When Orica Consumer Products (OCP) sold its industrial paints division in 1998 to focus its attention on the decorative coatings business, it asked Tony Green to design a New Technology Centre

As products become more complex, firms need to collaborate more with each other and also with their clients to be able to deliver new more capable systems

Ruth Beran talks with Iatia boss Charles Laycock about the importance of being smart and flexible in designing a good biotech business model. [ + ]

Southern Cross Equities biotech analyst Stuart Roberts was behind the recent DNA, Devices and Dealers conference in Sydney. Here, he explains his passion for hanging out with biotech's true believers. [ + ]

What are the odds that Australians' precious nest eggs be used to invest in something as risky as biotech? Well guess what -- it's already happening, and governments face pressure to free up more superannuation funds, writes Ruth Beran. [ + ]

Expat Kiwi Simon Moroney knows all too well the vagaries of the share market through his listed German biotech company, MorphoSys, writes Fiona Rotherham. [ + ]

The Australian science industry has grown in the last few years. While the progress being made by Australian industries is impressive, there are still many ways in which to improve efficiency and marketability on a global market